Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.
Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.
复制标题
全身炎症生物标志物预测接受立体定向消融放射治疗的早期非小细胞肺癌患者的生存率 - 单中心经验
DOI：
10.7150/jca.21703
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Sun Y
中科院分区：
文献类型：
--
作者：
Luo H;Ge H;Cui Y;Zhang J;Fan R;Zheng A;Zheng X;Sun Y
背景：越来越多的证据表明，在各种肿瘤治疗后，全身性炎症与生存之间存在关系。然而，早期非小细胞肺癌（NSCLC）立体定向消融放疗（SABR）后系统性炎症与生存的相关性尚未得到很好的证实。患者和方法：我们回顾性分析了2011年至2015年在单一机构接受SABR治疗的新诊断的早期NSCLC患者。计算中性粒细胞-淋巴细胞比率（NLR）、血小板-淋巴细胞比率（PLR）和淋巴细胞-单核细胞比率（LMR）作为全身性炎症的生物标志物。总生存期（OS）是第一个终点。采用受试者工作特征（ROC）确定OS的分界点。采用单因素和多因素Cox比例风险回归分析与OS相关的潜在因素。结果：在符合分析条件的63例患者中。SBRT后中位随访时间为29.5个月（8-67个月），3年OS为74.2%。经ROC分析，NLR、PLR和LMR的最佳临界值分别为2.06、199.55和4.0。NLR≤2.06组（p=0.028）、PLR≤199.55组（p=0.001）、LMR≤4.0组（p=0.046）生存获益显著。单因素分析表明，低NLR （p=0.011）、低PLR （p=0.003）和高LMR （p=0.014）与生存率提高相关。多因素分析显示，高PLR （p=0.033）和低LMR （p=0.046）是预后不良的独立因素。结论：在接受SABR治疗的早期NSCLC患者中，预处理NLR、PLR和LMR可被认为是有效的OS预后指标。这些指标可以提供可靠和方便的预测指标，以确定哪些患者将受益于SABR。
Background: Increasing evidence indicates a relationship between systemic inflammation and survival following treatment in various tumors. However, the correlation of systematic inflammation with survival after stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC) has not been well established. Patients and methods: We retrospectively analyzed patients with newly diagnosed early stage NSCLC treated with SABR in a single institution from 2011 to 2015. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte- monocyte ratio (LMR) were calculated as systemic inflammation biomarkers. Overall survival (OS) was the first end-point. Receiver operating characteristic (ROC) was used to determine cut-off points for OS. Univariate and multivariate Cox proportional hazards regression were used to investigate the potential factors associated with OS. Results: In the 63 patients who were eligible for analysis. The median follow up after SBRT was 29.5 months (range 8-67 months) while the 3-year OS was 74.2%. Based on ROC analysis, optimal cut-off values of NLR, PLR, and LMR were 2.06, 199.55 and 4.0, respectively. Significant survival benefit was found in the NLR ≤2.06 group (p=0.028), PLR≤199.55 group (p=0.001), and LMR˃4.0 group (p=0.046). Univariate analysis indicated that low NLR (p=0.011), low PLR (p=0.003), and high LMR (p=0.014) were correlated with improved survival. Multivariate analysis indicated that high PLR (p=0.033) and low LMR (p=0.046) were independent prognostic factors for poor survival. Conclusions: In patients of early stage NSCLC who received SABR, pretreatment NLR, PLR, and LMR could be considered useful prognostic indicators of OS. These metrics may provide reliable and convenient predictors to identify patients who would benefit from SABR.
登录
查看更多内容
影响因子：
51.1
作者：
Chang, Joe Y.;Senan, Suresh;Paul, Marinus A.;Mehran, Reza J.;Louie, Alexander V.;Balter, Peter;Groen, Harry J. M.;McRae, Stephen E.;Widder, Joachim;Feng, Lei;van den Borne, Ben E. E. M.;Munsell, Mark F.;Hurkmans, Coen;Berry, Donald A.;van Werkhoven, Erik;Kresl, John J.;Dingemans, Anne-Marie;Dawood, Omar;Haasbeek, Cornelis J. A.;Carpenter, Larry S.;De Jaeger, Katrien;Komaki, Ritsuko;Slotman, Ben J.;Smit, Egbert F.;Roth, Jack A.
通讯作者：
Roth, Jack A.
影响因子：
7
作者：
Lepperdinger G
通讯作者：
Lepperdinger G
影响因子：
9.6
作者：
Howington, John A.;Blum, Matthew G.;Murthy, Sudish C.
通讯作者：
Murthy, Sudish C.
影响因子：
20.4
作者：
Goldstraw, Peter;Crowley, John;Sobin, Leslie
通讯作者：
Sobin, Leslie
影响因子：
2.1
作者：
Martin, H. L.;Ohara, K.;Khattak, M. A.
通讯作者：
Khattak, M. A.